Halozyme Therapeutics, Inc. $HALO Shares Sold by Aurora Investment Counsel

Aurora Investment Counsel decreased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 26.3% in the 1st quarter, HoldingsChannel reports. The fund owned 18,452 shares of the biopharmaceutical company’s stock after selling 6,583 shares during the quarter. Aurora Investment Counsel’s holdings in Halozyme Therapeutics were worth $1,193,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Allworth Financial LP increased its stake in Halozyme Therapeutics by 322.5% in the 3rd quarter. Allworth Financial LP now owns 39,736 shares of the biopharmaceutical company’s stock valued at $2,914,000 after purchasing an additional 30,331 shares in the last quarter. Element Squared LLC purchased a new stake in Halozyme Therapeutics during the fourth quarter worth $1,193,000. CWA Asset Management Group LLC purchased a new stake in Halozyme Therapeutics during the fourth quarter worth $907,000. Assenagon Asset Management S.A. acquired a new stake in Halozyme Therapeutics in the fourth quarter valued at $4,851,000. Finally, Paragon Capital Management Inc. acquired a new stake in Halozyme Therapeutics in the fourth quarter valued at $1,273,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 1,923 shares of the business’s stock in a transaction that occurred on Wednesday, July 8th. The shares were sold at an average price of $79.77, for a total value of $153,397.71. Following the completion of the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at $61,245,810.60. The trade was a 0.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $76.71, for a total transaction of $124,653.75. Following the transaction, the director directly owned 42,044 shares in the company, valued at $3,225,195.24. The trade was a 3.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 74,102 shares of company stock worth $5,205,798 over the last ninety days. 2.50% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Trading Up 0.3%

Halozyme Therapeutics stock opened at $77.81 on Friday. The stock has a market cap of $9.23 billion, a PE ratio of 27.99, a P/E/G ratio of 0.32 and a beta of 0.84. The stock has a 50-day moving average price of $72.03 and a 200 day moving average price of $70.20. Halozyme Therapeutics, Inc. has a 52 week low of $55.64 and a 52 week high of $82.26. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.06. The firm had revenue of $376.71 million during the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The firm’s revenue for the quarter was up 42.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Equities research analysts predict that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on HALO shares. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, June 16th. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. Morgan Stanley dropped their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Finally, Wall Street Zen raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Eight research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $81.60.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.